Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | RXRA | P19793 | 7/20 | 0.32 |
| ▸ | RXRB | P28702 | 6/20 | 0.32 |
| ▸ | RXRG | P48443 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17029104 | 0.80 | RXRA (0.32) | RXRARXRBRXRG | |
| SCHEMBL17029102 | 0.74 | CHRNA7 (0.38) | L3MBTL1 | |
| SCHEMBL28366278 | 0.68 | CYP1A2 (0.51) | L3MBTL1 | |
| SCHEMBL324644 | 0.67 | SLC6A3 (0.39) | L3MBTL1 | |
| SCHEMBL1369489 | 0.61 | KMT2A (0.52) | RXRARXRBRXRG | |
| SCHEMBL17029101 | 0.61 | SMN1; SMN2 (0.45) | L3MBTL1 | |
| SCHEMBL28056335 | 0.59 | BTK (0.31) | — | |
| SCHEMBL5544170 | 0.58 | S1PR2 (0.36) | — | |
| SCHEMBL4503647 | 0.58 | GRM5 (0.35) | RXRARXRBRXRG | |
| SCHEMBL28101028 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150259337-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF DASATINIB | CERBIOS-PHARMA SA (CH) | 2015-09-17 | — | — | US | disclosed |
| US-9115124-B1 | Process and intermediates for the preparation of dasatinib | CERBIOS-PHARMA SA (CH) | 2015-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259337-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF DASATINIB | ABL1, SRC, ABL2 | L3MBTL1 4303/4885RXRA 4720/4885RXRB 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.